Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 85 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ALK Positive Clear all

Conditions: ALK Positive Malignancies
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions: Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo); Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year to 39 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Ceritinib, Trametinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Davis, California • San Francisco, California

Conditions: Neoplasms
Interventions: Alectinib, Crizotinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Orange, California • Boston, Massachusetts

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
Interventions: Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions: SGR-1505; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions: Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib); Drug
Lead sponsor: Xcovery Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 14
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 10 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Alectinib, Bevacizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Tampa, Florida • Cleveland, Ohio

Conditions: ALK-positive Advanced NSCLC
Interventions: Crizotinib, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 4 more

Conditions: Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC
Interventions: lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions: Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 29
States / cities: Culver City, California • Los Angeles, California • Sacramento, California + 21 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions: Brigatinib; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer, Nonsmall Cell
Interventions: Crizotinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC)
Interventions: NVL-655; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Interventions: gilteritinib; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Fullerton, California • Orange, California • Edwards, Colorado + 7 more

Conditions: Non-Small-Cell Lung Cancer, NSCLC
Interventions: Lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Irvine, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lorlatinib, Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 34
States / cities: Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more

Conditions: Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Interventions: POISE; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-Negative
Interventions: Autologous C7R.CD30-CAR-EBVSTs; Biological
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 16 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2044
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Study of SGR-1505 in Mature B-Cell Neoplasms

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Lorlatinib Continuation Study

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)